Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2018 (2018), Article ID 6131083, 5 pages
https://doi.org/10.1155/2018/6131083
Case Report

Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation

1Department for Cardiovascular Disease, Osijek University Hospital, J. Huttlera 4, 31000 Osijek, Croatia
2Department for Internal Medicine, Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Cara Hadrijana 10E, 31000 Osijek, Croatia

Correspondence should be addressed to K. Selthofer-Relatic; moc.liamg@citaler.refohtles

Received 4 January 2018; Revised 28 January 2018; Accepted 10 February 2018; Published 20 March 2018

Academic Editor: Assad Movahed

Copyright © 2018 K. Selthofer-Relatic. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. A. Zarate and R. J. Hopkin, “Fabry’s disease,” The Lancet, vol. 372, pp. 1427–1435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Yousef, P. M. Elliot, F. Cecchi et al., “Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis,” European Heart Journal, vol. 34, no. 11, pp. 802–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. R. Hsu, S. C. Hung, F. P. Chang et al., “Later onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation,” Journal of the American College of Cardiology, vol. 68, no. 23, pp. 2554–2563, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Chimenti, M. Pieroni, E. Morgante et al., “Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy,” Circulation, vol. 110, no. 9, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. W. R. Wilcox, J. P. Oliveira, R. J. Hopkin et al., “Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry,” Molecular Genetics and Metabolism, vol. 93, no. 2, pp. 112–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. P. Germain, “Fabry disease,” Orphanet Journal of Rare Diseases, vol. 5, no. 1, p. 30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Namdar, “Electrocardiographic changes and arrhythmia in Fabry disease,” Frontiers in Cardiovascular Medicine, vol. 3, p. 7, 2016. View at Publisher · View at Google Scholar
  8. C. Kapmann, A. Linhart, F. Baehner et al., “Onset and progression of the Anderson-Fabry disease related cardiomyopathy,” International Journal of Cardiology, vol. 130, no. 3, pp. 367–373, 2008. View at Google Scholar
  9. R. Schiffmann, D. Warnock, M. Banikazemi et al., “Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 7, pp. 2102–2111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Linhart, C. Kampmann, J. L. Zamorano et al., “Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey,” European Heart Journal, vol. 28, no. 10, pp. 1228–1235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Arends, M. Biegstraaten, D. A. Hughes et al., “Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors,” PLoS One, vol. 12, no. 8, Article ID e0182379, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Roguljic and K. Selthofer-Relatic, “Different cardiovascular manifestations in a Fabry disease patient,” Case Report. ESC Portal, 2017, http://learn.escardio.org/clinicalcase/casedetail/e8b6cb67-b909-4b1d-af2e-c1694c4e26af. View at Google Scholar
  13. H. Mahrholdt, A. Wagner, R. M. Judd, U. Sechtem, and R. J. Kim, “Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies,” European Heart Journal, vol. 26, no. 15, pp. 1461–1474, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Niemann, S. Herrmann, K. Hu et al., “Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment,” JACC: Cardiovascular Imaging, vol. 4, no. 6, pp. 592–601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Meyer, P. van der Meer, J. P. van Tintelen, and M. P. van den Berg, “Sex differences in cardiomyopathies,” European Journal of Heart Failure, vol. 16, no. 3, pp. 238–247, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. M. Elliott, A. Anastasakis, M. A. Borger et al., “2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC),” European Heart Journal, vol. 35, no. 39, pp. 2733–2779, 2014. View at Google Scholar